Syros Pharmaceuticals (SYRS) Expected to Announce Quarterly Earnings on Wednesday

Syros Pharmaceuticals (NASDAQ:SYRS) is projected to announce its resultson Wednesday, March 25th. Analysts expect the company to announce earnings of ($0.1580) per share for the quarter.

Syros Pharmaceuticals Stock Performance

NASDAQ SYRS opened at $0.00 on Thursday. The company has a market capitalization of $5,366.40, a PE ratio of 0.00 and a beta of 1.31. Syros Pharmaceuticals has a 1-year low of $0.00 and a 1-year high of $0.10.

Syros Pharmaceuticals Company Profile

Syros Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company headquartered in Cambridge, Massachusetts, that is pioneering a new class of targeted therapeutics by focusing on the control of gene expression. Founded in 2015 as a spin-out from the Broad Institute, Syros leverages its proprietary gene control platform to identify and drug key noncoding regions of the genome that regulate disease-driving genes. The company’s approach aims to convert previously undruggable gene targets into precise medicines for patients with cancer and rare genetic disorders.

Syros’ lead development candidate, tamibarotene (SY-1425), is an oral, selective RARα agonist being evaluated in acute myeloid leukemia (AML) and high-risk myelodysplastic syndromes (MDS) characterized by RARA dependence.